Skip to main content

Table 1 Patients’ characteristics

From: Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis

Variable

Adjuvant chemotherapy

Observation

p-value

Matched observation group

p-value

Patients, n (%)

30 (100)

110 (100)

 

30 (100)

 

Age, years

  

< 0.001

 

0.8

 Median

76.2

79

 

76.7

 

 Min.–Max.

75–81

75–91

 

75–81

 

Gender, n (%)

  

0.084

 

0.58

 Male

22 (73)

59 (54)

 

19 (63)

 

 Female

8 (27)

51 (46)

 

11 (37)

 

Smoking status, n (%)

  

0.364

 

0.22

 Never

6 (20)

32 (29)

 

3 (10)

 

 Former

20 (67)

56 (51)

 

18 (60)

 

 Current

4 (13)

22 (20)

 

9 (30)

 

CCI, n (%)

  

0.46

 

0.434

 0

7 (23)

21 (19)

 

5 (17)

 

 1

11(37)

31 (28)

 

8 (27)

 

 ≥ 2

12 (40)

58 (53)

 

17 (56)

 

Stage, n (%)

  

0.001

 

1

 II

3 (10)

48 (44)

 

3 (10)

 

 III

27 (90)

62 (56)

 

27 (90)

 

T status, n (%)

  

0.44

 

0.386

 1

1 (3)

2 (2)

 

2 (7)

 

 2

11 (37)

37 (34)

 

7 (23)

 

 3

7 (23)

43 (39)

 

11 (37)

 

 4

11 (37)

28 (25)

 

10 (33)

 

N status, n (%)

  

< 0.001

 

0.406

 0

6 (20)

43 (39)

 

7 (23)

 

 1

8 (27)

48 (44)

 

12 (40)

 

 2

16 (53)

19 (17)

 

11 (37)

 

PS ECOG, n (%)

  

0.206

 

0.3

 0

19 (63)

53 (48)

 

14 (47)

 

 1

11 (37)

57 (52)

 

16 (53)

 

Histopathology, n (%)

  

1

 

1

 Squamous

15 (50)

55 (50)

 

16 (53)

 

 Non-squamous

15 (50)

55 (50)

 

14 (47)

 

Type of surgery, n (%)

  

0.568

 

0.67

 Lobar resection

23 (76)

89 (81)

 

22 (74)

 

 Sub-lobar resection

5 (17)

11 (10)

 

4 (13)

 

 Pneumonectomy

2 (7)

10 (9)

 

4 (13)

 
  1. CCI, Charlson Comorbidity Index; Max., Maximum; Min., Minimum; PS ECOG, performance status according to Eastern Cooperative Oncology Group, T, tumor